APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

Summary

Background Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series. Methods and findings We report here a novel update (2012–2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers—total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42—in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification. Conclusions Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.

Related articles

• History and Development of Medical Technology in the Philippines

  This document provides a comprehensive overview of the history and evolution of medical technology in the Philippines, particularly during the Spanish and American occupations. It details the establishment of hospitals, key figures in medical advancements, and the development of public health initiatives.

• Functions of Management in Medical Laboratory Settings

  This document outlines the functions of management within a medical laboratory context, detailing key management principles such as planning, organizing, directing, and controlling, along with their applications in laboratory operations.

• Inflammation and Repair

  This chapter provides an overview of inflammation, defining its features and discussing the sequential steps involved, including recognition of harmful agents, recruitment of immune cells, and the process of tissue repair. It examines both acute and chronic inflammation, including their causes, mediators, and clinical implications.

• Overview of Radiographic Imaging Techniques

  This document presents personal notes detailing the principles and techniques of radiographic imaging, including the operation of X-ray equipment, technical competencies of radiographers, and the anatomy of the X-ray tube. It aims to provide a comprehensive understanding of radiography as both an art and science.

• IMAGE PRODUCTION & FILM PROCESSING

  This document provides comprehensive guidelines for the dark room processes involved in radiography, including the environmental controls, required equipment, and procedures for efficient film processing.